Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma: early-phase trial registry
10 of 30 indexed Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 10 currently recruiting · #519 of 28,707 conditions by registered trial count
Carcinoma: 30 US clinical trials tracked, 10 recruiting.
Carcinoma is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 3 of these trials.
Enrollment posture brief
Registry condition carcinoma
OPEN 10 | RECR 33% | LATE 5 | EARLY 18 | RANK #519 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Carcinoma lists 10 open slots (33% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoma is recruiting below its size-band peers.
10 of 30 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Carcinoma trials is spread across many organizations.
AstraZeneca accounts for 3 of 30 trials (10%). 25 distinct sponsors appear on at least one study for this condition label.
-
Typical Carcinoma enrolment sits around 103 participants.
Median target enrolment is 103 among the 30 trials that report a genuine target (sentinel values excluded). 14 of those (46.7%) plan for fewer than 100 participants.
-
Carcinoma research is mostly interventional.
27 interventional and 3 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer
Roswell Park Cancer Institute
NCT06456411
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Marengo Therapeutics
NCT05592626
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
AstraZeneca
NCT05261399
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18
NCT04787042
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Travera
NCT05461430
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Alain Algazi
NCT03708224
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Zachary Zumsteg
NCT06445114
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
NCT05559879
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma
NCT05283226
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Roberto Vargas
NCT05065736
Exercise Exposure Data Collection in Patients Undergoing Tumor Molecular Profiling
Memorial Sloan Kettering Cancer Center
NCT03208374
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
AstraZeneca
NCT03778229
Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer
Alliance for Clinical Trials in Oncology
NCT03857620
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT04483778
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
NCT03091192
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT03618381
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Washington University School of Medicine
NCT01061515
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
VA Office of Research and Development
NCT00847912
Early Diagnosis of Pulmonary Nodules
Integrated Diagnostics
NCT01752114
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Amgen
NCT00838201
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis Pharmaceuticals
NCT00719264
Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings
UNC Lineberger Comprehensive Cancer Center
NCT04931251
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin
NCT02705105
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
NCT00770536
Smartphone App for Cancer Medication Adherence
Columbia University
NCT05225090
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Xoft
NCT00742222
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
TaiRx
NCT02507544
A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma
Spectrum Pharmaceuticals
NCT00613691
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
NCT01916135
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
Anza Therapeutics
NCT00327652
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 5 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoma page
30 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Carcinoma trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoma condition card totals 30 registered trials; most-linked intervention Savolitinib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.